REgistry of Selective Internal Radiation Therapy in TaiwaN (RESIN)

Taipei Veterans General Hospital, Taiwan100 enrolled

Overview

All study objectives will be assessed in HCC patients or colorectal cancer patients with secondary metastases in the liver, respectively.

All study objectives will be assessed in HCC patients or colorectal cancer patients with secondary metastases in the liver, respectively. 1. Primary objective: * To observe the safety of SIR-Spheres® microspheres therapy (SIRT)by, * Adverse events and serious adverse events (non-specific and radiation specific) * Changes in liver function parameters * To observe the efficacy of SIR-Spheres® microspheres therapy by, assessing the best overall response rate after SIRT 2. Secondary objectives: * To observe the efficacy of SIRT by, * Overall survival (OS) * Overall/objective response rate (ORR) * Time-to-progression * Time-to-liver progression * Progression-free survival * To observe the changes in clinical presentation after SIRT by, * ECOG score * Child-Pugh score * Percentage of subjects with down-staging or down-sizing of treated lesion to resection, transplantation, or radiofrequency ablation (RFA) * To observe the practice pattern of SIRT by, * Median dosage (GBq) * Number of SIRT sessions received by subjects 3. Exploratory objectives: * To explore prognostic factors for disease progression after SIRT by comparing the following parameters: * Number of tumors in subjects prior to SIRT * Median tumor size in subjects prior to SIRT * Location of tumor in subjects treated with SIRT (hepatic segment or lobe) * Number of prior TACE treatment in subjects * Antiviral therapy subjects HCC

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Hepatocellular Carcinoma

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria, Patients who meet all inclusion criteria will be included: * Males or non-pregnant females, at least 18 years of age (inclusive). * Patients with clinically confirmed hepatocellular carcinoma (HCC) OR adenocarcinoma of colon/rectum with liver metastasis. * Patients with liver dominant disease. * Tumor burden ≤ 70% of total liver volume. * HCC patients with child-Pugh Score class A or B. * HCC patients with Barcelona-Clinic Liver Cancer (BCLC) stage A-C. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. * Patients who are unsuitable for resection or immediate liver transplantation or who cannot be optimally treated with local ablation. * Patients who have provided written informed consent. Exclusion Criteria, Patients who meet any exclusion criteria will be excluded: * Patients known to be hypersensitive to any component of study product. * Female patients who are pregnant or lactating. Women of child bearing potential who disagree to practice medically recognized birth control methods throughout the study (from Screening to approximately 6 months post SIRT). Medically recognized birth control methods include hormonal contraceptives, intrauterine device/IUD, barrier device, or abstinence. With the exception of women who had been surgically sterilized (defined as having undergone hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation alone is not considered sufficient), or one year post-menopausal. Withdrawal criteria: * Patients consent withdrawal. * Lost to follow-up for 2 consecutive visits.

Locations (1)

Taipei Veterans General Hospital

Taipei, Taiwan

RECRUITING

Outcomes

Primary Outcomes

Safety as per CTCAE 4.03, incidence of AEs and baseline change in liver function paired t-test or Wilcoxon signed rank test.

Toxicity will be accessed according to CTCAE v4.03. The incidence of adverse events will be summarized and the change in baseline liver function will be assessed by paired t-test or Wilcoxon signed rank test.

Time frame: 6 months

Secondary Outcomes

Overall survival

Overall survival (OS) is determined for all enrolled subjects from Day 0 to the date of death or last contact.

Time frame: 1 year

Overall Response Rate per RECIST 1.1 and mRECIST

Liver tumor assessments for CRC will be evaluated by RECIST v1.1; and tumor assessments for HCC will be evaluated by mRECIST. \- Objective Response Rate is defined as the proportion of subjects with tumor size reduction (i.e. the combined proportion of subjects with CR and PR) from Day 0 until documented tumor progression.

Time frame: 1 year

Time-to-progression per RECIST 1.1 and mRECIST

The time-to-progression (TTP) is calculated by the time from Day 0 to the date of disease progression (PD).

Time frame: 1 year

Time-to-liver progression per RECIST 1.1 and mRECIST

The time-to-liver progression is calculated by the time from Day 0 to the date of tumor progression (PD) in intrahepatic lesions.

Time frame: 1 year

Progression-free survival

Progression free survival (PFS) is determined for all enrolled patients from Day 0 until tumor progression or patient death.

Time frame: 1 year

Central Contacts

Rheun-Chuan Lee, M.D.

CONTACT

+886-2-28712121 vghtpeyttrium90@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.